Atlas Trials

KRAS Activating Mutation

6 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch KRAS Activating Mutation

RecordFirmDate
Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer (NCT05669482)Verastem, Inc.2023-03-22
Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients (NCT05375994)Verastem, Inc.2022-08-01
Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients (NCT05074810)Verastem, Inc.2022-04-12
Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (≥ 50%) NSCLC Patients (NCT04470674)Shirish M Gadgeel2021-04-06
A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer (NCT04620330)Verastem, Inc.2020-12-31
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies (NCT04566393)xCures

Track KRAS Activating Mutation automatically

Every clearance here is in the API, with alerts when new ones post.